• 1. An atlas of endohedral Sc2S cluster fullerenes?
  Li-Hua Gan,Rui Wu,Jian-Lei Tian,Patrick W. Fowler Phys. Chem. Chem. Phys., 2017,19, 419-425
• 2. Aluminium complexes with thio-phosphorus ligands: syntheses and characterisations of [Al2(CyPS3)2(CyPHS2)2] and [Al(S2PPh2)3]?
  Robert P. Davies,Maria A. Giménez,Laura Patel,Andrew J. P. White Dalton Trans., 2008, 5705-5707
• 3. Acetyl protected thiol methacrylic polymers as effective ligands to keep quantum dots in luminescent standby mode?
  Marta Liras,Isabel Quijada-Garrido,Marta Palacios-Cuesta,Sonia Mu?oz-Durieux,Olga García Polym. Chem., 2014,5, 433-442
• 4. An insight into the role of side chains in the microstructure and carrier mobility of high-performance conjugated polymers?
  Jianyao Huang,Dong Gao,Zhihui Chen,Weifeng Zhang Polym. Chem., 2021,12, 2471-2480
• 5. An aquatic host–guest complex between a supramolecular G-quadruplex and the anticancer drug doxorubicin?
  José M. Rivera,Mariana Martín-Hidalgo,Jean C. Rivera-Ríos Org. Biomol. Chem., 2012,10, 7562-7565

• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Pyridines and derivatives 2-halopyridines
• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Pyridines and derivatives Halopyridines 2-halopyridines

Recent Advances in the Study of 5-Bromo-1-methyl-1H-pyrazolo[3,4-c]pyridine (CAS: 1337880-46-2)

5-Bromo-1-methyl-1H-pyrazolo[3,4-c]pyridine (CAS: 1337880-46-2) is a heterocyclic compound that has garnered significant attention in the field of chemical biology and medicinal chemistry due to its potential applications in drug discovery and development. Recent studies have focused on its synthesis, structural modifications, and biological activities, particularly in the context of targeting various disease pathways. This research brief aims to provide an overview of the latest findings related to this compound, highlighting its therapeutic potential and the methodologies employed in its study.

The synthesis of 5-Bromo-1-methyl-1H-pyrazolo[3,4-c]pyridine has been optimized in recent years to improve yield and purity, which are critical for its application in high-throughput screening and drug development. Researchers have employed advanced techniques such as microwave-assisted synthesis and catalytic bromination to achieve efficient and scalable production. These methodological advancements have facilitated the exploration of its pharmacological properties, including its interactions with specific biological targets.

One of the key areas of interest is the compound's role as a kinase inhibitor. Kinases are enzymes that play a pivotal role in cell signaling and are often implicated in cancer and inflammatory diseases. Preliminary studies suggest that 5-Bromo-1-methyl-1H-pyrazolo[3,4-c]pyridine exhibits selective inhibition against certain kinase isoforms, making it a promising candidate for further development. In vitro assays have demonstrated its ability to modulate kinase activity, with potential implications for targeted therapy in oncology.

In addition to its kinase inhibitory properties, recent research has explored the compound's potential in central nervous system (CNS) disorders. Structural analogs of 5-Bromo-1-methyl-1H-pyrazolo[3,4-c]pyridine have shown affinity for neurotransmitter receptors, suggesting possible applications in treating neurological conditions such as depression and anxiety. These findings are supported by computational modeling and binding studies, which provide insights into the compound's mechanism of action at the molecular level.

Another noteworthy development is the investigation of 5-Bromo-1-methyl-1H-pyrazolo[3,4-c]pyridine in combination therapies. Researchers are exploring its synergistic effects with existing drugs to enhance therapeutic efficacy and overcome drug resistance. For instance, studies in cancer cell lines have indicated that the compound can potentiate the effects of chemotherapeutic agents, thereby reducing the required dosage and minimizing side effects. These findings underscore the compound's versatility and potential for integration into multimodal treatment regimens.

Despite these promising results, challenges remain in the clinical translation of 5-Bromo-1-methyl-1H-pyrazolo[3,4-c]pyridine. Issues such as bioavailability, metabolic stability, and off-target effects need to be addressed through further preclinical studies. Recent efforts have focused on structural optimization to improve these pharmacokinetic properties, with some derivatives showing enhanced stability and reduced toxicity in animal models.

In conclusion, 5-Bromo-1-methyl-1H-pyrazolo[3,4-c]pyridine (CAS: 1337880-46-2) represents a versatile scaffold with significant potential in drug discovery. Its applications span from kinase inhibition to CNS modulation, and ongoing research continues to uncover new therapeutic avenues. Future studies should prioritize the optimization of its pharmacological profile and the exploration of its mechanisms in vivo to pave the way for clinical development.

• 1326715-73-4(3-bromo-1-methyl-pyrazolo[3,4-c]pyridine)
• 1289014-53-4(4-Bromo-1-methyl-1H-pyrazolo[4,3-c]pyridine)
• 1434054-04-2(5-Bromo-2,3-dimethyl-2H-pyrazolo[3,4-c]pyridine)
• 1822621-83-9
• 1032943-41-1(4-Bromo-1-methyl-1H-pyrazolo[3,4-c]pyridine)
• 1434054-03-1(5-Bromo-1,3-dimethyl-1H-pyrazolo[3,4-c]pyridine)
• 1638764-71-2(6-Bromo-1-methyl-1H-pyrazolo[4,3-c]pyridine)
• 2219366-71-7(5-bromo-1-methyl-1H-pyrazolo4,3-bpyridine)
• 2089292-88-4(5-bromo-2-methyl-pyrazolo[3,4-c]pyridine)
• 1563177-30-9(5-bromo-2-methyl-2H-pyrazolo4,3-bpyridine)